Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
First Claim
Patent Images
1. A synthetic, oligonucleotide of 14 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to a 14-30 nucleotide region of a natural antisense polynucleotide of a Uncoupling Protein 2 (UCP2) polynucleotide having SEQ ID NO;
2 or 3 and specifically hybridizes to at least one nucleotide of a target region of a natural antisense polynucleotide of said Uncoupling Protein 2 (UCP2) polynucleotide selected from nucleotides 1 to 174 of SEQ ID NO;
2 or nucleotides 1 to 267;
375-575 and 685-802 of SEQ ID NO;
3 and upregulates the function and/or expression of the Uncoupling Protein 2 (UCP2) gene in vivo or in vitro as compared to a normal control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Uncoupling Protein 2 (UCP2), in particular, by targeting natural antisense polynucleotides of Uncoupling Protein 2 (UCP2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of UCP2.
-
Citations
15 Claims
-
1. A synthetic, oligonucleotide of 14 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to a 14-30 nucleotide region of a natural antisense polynucleotide of a Uncoupling Protein 2 (UCP2) polynucleotide having SEQ ID NO;
2 or 3 and specifically hybridizes to at least one nucleotide of a target region of a natural antisense polynucleotide of said Uncoupling Protein 2 (UCP2) polynucleotide selected from nucleotides 1 to 174 of SEQ ID NO;
2 or nucleotides 1 to 267;
375-575 and 685-802 of SEQ ID NO;
3 and upregulates the function and/or expression of the Uncoupling Protein 2 (UCP2) gene in vivo or in vitro as compared to a normal control. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)
- at least one modified sugar moiety;
-
12. A composition comprising an oligonucleotide and a pharmaceutically acceptable excipient, wherein the oligonucleotide has at least about 95% sequence identity as compared to any one of the nucleotide sequences set forth as SEQ ID NOS:
- 4, 5, 11 and 13.
Specification